KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.96

Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial.

Salomon Manier, Meletios-Athanasios Dimopoulos, Xavier P Leleu, Philippe Moreau, Michele Cavo, Hartmut Goldschmidt, Robert Z Orlowski, Muriel Tron, Christina Tekle, Marie-France Brégeault, Andrea T Shafer, Meral Beksac, Thierry Facon

Haematologica 110(9) 2139-2150

PMID40109195
PMCIDPMC12399942
DOI10.3324/haematol.2024.287200
发表日期2025-03-20
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1.:森林图/亚组分析图;Figure 2.:森林图/亚组分析图;Figure 3.:生活质量量表图;Figure 4.:森林图/亚组分析图。
摘要

摘要

Patients with multiple myeloma (MM) meeting frailty criteria have worse outcomes than those identified as non-frail. Here, we present a post hoc subgroup analysis of IMROZ, a global, phase III, open-label study investigating isatuximab (Isa) with bortezomib, lenalidomide, and dexamethasone (VRd) followed by Isa-Rd (N=265) versus VRd followed by Rd (N=181) in newly diagnosed transplant-ineligible MM (Ti NDMM) patients using the simplified International Myeloma Working Group (sIMWG) frailty score. Although patients aged >80 years were excluded, there was no exclusion for patients meeting frailty criteria. All patients received standard VRd/Rd dosing; Isa-VRd patients received intravenous Isa (cycle 1, 10 mg/kg once weekly; cycles 2-17, once every 2 weeks; subsequent cycles, once every 4 weeks). Patients with a frailty score of 0/1 were considered nonfrail; scores ≥2 were frail. Using this scoring, 26.7% of patients were frail (26.0% Isa-VRd; 27.6% VRd), and 72.0% non-frail (72.8% Isa-VRd; 70.7% VRd). After a median follow-up of 59.7 months, Isa-VRd significantly improved progression-free survival versus VRd in frail patients (hazard ratio [HR] =0.518; 95% confidence interval [CI]: 0.294-0.912; P=0.0227) and non-frail patients (HR=0.615; 95% CI: 0.419-0.903; P=0.0131). Significantly more frail patients receiving Isa-VRd than VRd achieved minimal residual disease negativity and complete response (odds ratio=3.459; 95% CI: 1.495-8.006; P=0.0030 at 10-5 by next-generation sequencing). Rates of treatment-emergent adverse events leading to definitive discontinuation were similar between both arms regardless of frailty status. This post hoc subgroup analysis of the IMROZ trial demonstrated that Isa-VRd is an effective option with a manageable safety profile for frail patients with Ti NDMM (clinicaltrials gov. Identifier: NCT03319667).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Kaplan-Meier curves of progression-free survival for the frail and non-frail subgroups. CI: confidence interval; d: dexameth-asone; HR: hazard ratio; Isa: isatuximab; R: lenalidomide; V: bortezomib; NR: not reached; mo: months; PFS: progression-free survival.
非 KM Figure
Figure 2.Summary of responses and minimal residual disease status for frail and non-frail subgroups. (A) Depth of response and (B) minimal residual disease negativity (MRD-) rates. CI: confidence interval; ≥CR: complete response or better; d: dexamethasone; Isa: isatuximab; OR: odds ratio; ORR: overall response rate; PR: partial response; R: lenalidomide; sCR: stringent complete response; V: bortezomib; ≥VGPR: very good partial response or better.
非 KM Figure
Figure 3.Quality of life as measured by EORTC-QLQ-C30 in the frail and non-frail subgroups. (A) Frail subgroup. (B) Non-frail subgroup. d: dexamethasone; EORTC-QLQ-C30: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30; EOT: end of treatment; Fu: follow-up; Isa: isatuximab; R: lenalidomide; V: bortezomib.
非 KM Figure
Figure 4.Kaplan-Meier estimates of overall survival for the frail and non-frail subgroups. CI: confidence interval; d: dexameth-asone; HR: hazard ratio; Isa: isatuximab; R: lenalidomide; V: bortezomib; NR: not reached.
非 KM Figure